BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed CADL catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:49ea5ede419357330b6e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:CADL P2 readout (est.): A Biomarker Study in Men With Localized Pro
 state Cancer Treated With Aglatimagene Besadenovec
DESCRIPTION:A Biomarker Study in Men With Localized Prostate Cancer Treated
  With Aglatimagene Besadenovec\nNCT07332000 | PHASE2 | RECRUITING | sponso
 r: Candel Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker CADL (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT07332000\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07332000
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
